{
    "clinical_study": {
        "@rank": "65675", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with\n      trientine therapy as initial treatment in patients with Wilson disease presenting\n      neurologically."
        }, 
        "brief_title": "Study of Tetrathiomolybdate in Patients With Wilson Disease", 
        "condition": "Wilson Disease", 
        "condition_browse": {
            "mesh_term": "Hepatolenticular Degeneration"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This a double blind, randomized study. Patients are randomized into one of\n      two treatment arms.\n\n      Arm I: Patients receive tetrathiomolybdate (TM) 3 times a day with meals and 3 times a day\n      between meals for 8 weeks in the absence of neurologic deterioration or unacceptable\n      toxicity.\n\n      Arm II: Patients receive trientine therapy for 8 weeks in the absence of neurologic\n      deterioration and unacceptable toxicity.\n\n      Additional therapy (off study): Patients in the TM group may receive maintenance zinc, while\n      those in the trientine group may continue on trientine or switch to zinc."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Wilson disease presenting with neurologic or psychiatric symptoms\n\n          -  No concurrent seizure activity\n\n          -  No white matter lesions on brain magnetic resonance imaging\n\n        --Prior/Concurrent Therapy--\n\n          -  No more than 2 weeks of prior therapy\n\n          -  No penicillamine or trientine for longer than 2 weeks\n\n        --Patient Characteristics--\n\n          -  Hepatic: No severe hepatic failure\n\n          -  Other: No psychiatric or medical contraindication to protocol therapy\n\n          -  Not pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "90", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004339", 
            "org_study_id": "NCRR-M01RR00042-1850", 
            "secondary_id": [
                "UMMC-801", 
                "UMICH-FDU000505"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "tetrathiomolybdate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "trientine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Trientine", 
                "Tetrathiomolybdate", 
                "Molybdenum"
            ]
        }, 
        "keyword": [
            "Wilson disease", 
            "inborn errors of metabolism", 
            "rare disease"
        ], 
        "lastchanged_date": "May 8, 2006", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan", 
            "last_name": "George J. Brewer", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "reference": [
            {
                "PMID": "8198464", 
                "citation": "Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol. 1994 Jun;51(6):545-54."
            }, 
            {
                "PMID": "8859064", 
                "citation": "Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 1996 Oct;53(10):1017-25."
            }, 
            {
                "PMID": "16606763", 
                "citation": "Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006 Apr;63(4):521-7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004339"
        }, 
        "source": "National Center for Research Resources (NCRR)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Michigan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 1994", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2003"
    }, 
    "geocoordinates": {
        "University of Michigan": "42.281 -83.743"
    }
}